Phesgo and Tecentriq Performance and Approvals
Multiple Sclerosis: Ocrevus reaching 22% patient share
Ph Ill results for 6M SC Ocrevus expected in 2023
YoY CER growth
+14%
Q1 update
CHFM
1,750
+18%
1,500
+16%
1,250
+38%
1,000
750
500
250
0
Q1 20
Q121
Q1 22
Q123
US
Europe
International
Roche
• >300k patients treated globally
•
#1 treatment in US and EU-5, both in total share and new to
brand share
•
Higher retention rate than other MS medicines
•
Ph III (GAVOTTE/MUSETTE) high-dose Ocrevus recruitment
completion imminent
Outlook 2023
•
US/EU: Further market share gains and growth expected
•
⚫ Ph III (OCARINA II) Ocrevus SC with Q6M dosing in RMS &
PPMS data read out expected
•
First Ph II (FENopta) data for fenebrutinib in RMS expected
27
CER-Constant Exchange Rates; MS-multiple sclerosis; SC-subcutaneous; Q6M-every 6 months; RMS=relapsing MS; PPMS-primary progressive MSView entire presentation